2024-03-28T11:41:51Zhttp://repisalud.isciii.es/oai/requestoai:repisalud.isciii.es:20.500.12105/96412023-05-03T12:43:21Zcom_20.500.12105_15322com_20.500.12105_2051com_20.500.12105_2060com_20.500.12105_2052col_20.500.12105_16987col_20.500.12105_16978col_20.500.12105_16958col_20.500.12105_2061
00925njm 22002777a 4500
dc
Falcon-Neyra, Lola
author
Palladino, Claudia
author
Navarro Gómez, María Luisa
author
Soler-Palacín, Pere
author
González-Tomé, María Isabel
author
De Ory, Santiago J
author
Frick, Marie Antoinette
author
Fortuny, Clàudia
author
Noguera-Julian, Antoni
author
Moreno, Elena Bermúdez
author
Santos, Juan Luis
author
Olbrich, Peter
author
López-Cortés, Luis F
author
Briz, Veronica
author
Neth, Olaf
author
2016-06
To assess the safety and efficacy of rilpivirine in combination with emtricitabine and tenofovir (RPV/FTC/TDF) as a once-daily single-tablet regimen (STR) in HIV-1-infected children and adolescents we performed a multicenter case series study of HIV-1-infected patients. Inclusion criteria were initiation of therapy with RPV/FTC/TDF before the age of 18. Patients were divided into undetectable viral load (uVL) group, HIV-1 RNA < 20 copies/mL on stable combined antiretroviral therapy (cART), and detectable viral load (dVL) group, HIV-1 RNA ≥ 20 copies/mL at RPV/FTC/TDF initiation. Patients were monitored from the date of RPV/FTC/TDF initiation until June 30, 2015, RPV/FTC/TDF discontinuation or failure to follow-up. Seventeen patients (8 in uVL and 9 in dVL group) with age between 11.6 and 17.6 were included. Reasons for switching were toxicity (n = 4) and simplification (n = 4) in uVL; viral failure (n = 8) and cART initiation (n = 1) in the dVL group. After a median follow-up of 90 (uVL) and 40 weeks (dVL), 7/8 (86%) patients maintained and 8/9 (89%) achieved and maintained HIV-1 suppression. Median CD4 count increased from 542 to 780/μL (uVL, P = 0.069) and 480 to 830/μL (dVL, P = 0.051). Five patients (2 in uVL and 3 in dVL) improved their immunological status from moderate to no immunosuppression. Serum lipid profiles improved in both groups; cholesterol dropped significantly in the dVL group (P = 0.008). Grade 1 laboratory adverse events (AEs) were observed in 3 patients. No clinical AEs occurred. Adherence was complete in 9 patients (5 in uVL and 4 in dVL); 1 adolescent interrupted treatment. Once-daily STR with RPV/FTC/TDF may be a safe and effective choice in selected HIV-1-infected adolescents and children.
Medicine (Baltimore) . 2016 Jun;95(24):e3842.
0025-7974
http://hdl.handle.net/20.500.12105/9641
27310962
10.1097/MD.0000000000003842
1536-5964
Medicine
Off-label use of rilpivirine in combination with emtricitabine and tenofovir in HIV-1-infected pediatric patients: A multicenter study